RxDoctor Payments Data

Tamra Cox, NP

Family · Farmington, ARNPI 1134657836

Payments from drug & device makers

$2,360in general payments, 2019–2025

Across 144 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$969
  • Amgen$527
  • GSK$204
  • Boehringer Ingelheim$162
  • UCB, Inc.$159
  • Lilly USA, LLC$126
  • plus $213 from 6 others

What the payments were for

  • Food & beverage$2,360100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie78$969
Amgen(2 entities)24$527
GSK11$204
Boehringer Ingelheim4$162
UCB, Inc.8$159
Lilly USA, LLC6$126
Fresenius Kabi USA, LLC4$64
Novo Nordisk4$54
Abbott2$37
Pfizer1$23
Dexcom, Inc.1$20
Merck1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,360 in reported general payments places this provider in the 80th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$1,272
Medicare patients
30
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$40,572
OzempicSemaglutide20$18,777
EliquisApixaban17$17,999
JardianceEmpagliflozin14$10,404
FarxigaDapagliflozin Propanediol11$6,036
Albuterol Sulfate HfaAlbuterol Sulfate49$1,342
Omeprazole31$761
MethotrexateMethotrexate Sodium17$491
Ondansetron OdtOndansetron31$343
Gabapentin16$268
Azithromycin57$257
Atorvastatin Calcium36$252
Lisinopril44$248
Losartan Potassium20$244
Ezetimibe12$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$204$40,57260 claims
Novo NordiskOzempic$54$18,77720 claims
PfizerEliquis$23$17,99917 claims
Boehringer IngelheimJardiance$162$10,40414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,103 family providers in Arkansas.

Other family in Farmington

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →